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Abstract
Background: AIDS-associated cryptococcal meningitis has a high mortality. Fluconazole was the
only systemic antifungal therapy available in our centre. From 1999–2001 we used low-dose
fluconazole (200 mg daily initially), and did not offer therapy to patients perceived to have poor
prognoses. In 2001 donated fluconazole became available, allowing us to use standard doses (400
mg daily initially). Antiretroviral therapy was not available during the study period.
Methods: Retrospective chart review of adult patients before and after the fluconazole donation.
Results: 205 patients fulfilled the inclusion criteria, 77 before and 128 after the donation. Following
the donation fewer patients received no antifungal treatment (5% vs 19%, p = 0.002), and more
patients received standard-dose fluconazole (90% vs 6%, p < 0.001). In-hospital mortality was 25%.
Impaired consciousness, no antifungal treatment received and cerebrospinal fluid antigen titre >
1,000 were independent predictors of in-hospital mortality. Concomitant rifampicin did not affect
in-hospital survival. Thirteen patients were referred to the tertiary referral hospital and received
initial treatment with amphotericin B for a mean of 6 days – their in-hospital survival was not
different from patients who received only fluconazole (p = 0.9). Kaplan-Meier analysis showed no
differences in length of survival by initial treatment with standard or low doses of fluconazole (p =
0.27 log rank test); median survival was 76 and 82 days respectively.
Conclusion: Outcome of AIDS-associated cryptococcal meningitis is similar with low or standard
doses of fluconazole. The early mortality is high. Initial therapy with amphotericin B and other
measures may be needed to improve outcome.
Background
AIDS-associated cryptococcal meningitis is a severe
opportunistic infection with a high mortality, even in
developed countries [1]. Early mortality rates in cohorts
from the United States have ranged from 11 to 45% [2,3].
Amphotericin B and flucytosine, given for 2 weeks, fol-
lowed by fluconazole 400 mg daily (reduced to 200 mg
daily after 10 weeks) is considered the treatment of choice
for AIDS-associated cryptococcal meningitis [4]. The mor-
tality rate with this regimen in a clinical trial was 9.4 %
[5]. This low mortality rate is unlikely to be replicated in
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cohort studies as patients with coma, who have a poorer
prognosis, were excluded from the trial.
In developing countries access to antifungal therapy is
limited [6]. In sub-Saharan Africa reported mortality rates
with antifungal treatment are very high: median survival
of 19 days in a Zambian study [7] and 64% in-hospital
mortality in a South African study [8]. Factors that are
likely to contribute to this high mortality rate include lim-
ited access to antifungal therapy, late presentation, inabil-
ity to adequately monitor intracranial pressure, no use of
cotrimoxazole prophylaxis and no access to antiretroviral
therapy.
In our centre we had no access to amphotericin B or flucy-
tosine, but had access to fluconazole. Initially, because
fluconazole was expensive, we selected patients with fair
prognoses and we used low doses: 200 mg daily for initial
therapy followed by 100 mg daily for maintenance. There
was evidence for this low dose approach: fluconazole 200
mg daily for initial therapy compared to amphotericin B
resulted in similar survival and time to negative cultures
[9]; and in another trial fluconazole 100 mg daily was
used as initial maintenance therapy [10]. Following a flu-
conazole donation programme by Pfizer Pharmaceuticals
[11] we were able to use conventional doses of flucona-
zole (400 mg daily for initial therapy followed by 200 mg
daily for maintenance). In this study we assess the out-
come of AIDS-associated cryptococcal meningitis before
and during the fluconazole donation programme.
Methods
A retrospective chart review was conducted at GF Jooste
hospital, a public sector secondary level hospital that
serves a population of approximately 1.3 million people
with a high HIV prevalence. All HIV-infected patients who
presented with a first episode of cryptococcal meningitis
between January 1999 and December 2002 were
included. Donated fluconazole became available in April
2001. Low dose fluconazole (200 mg daily for until CSF
was culture negative or for 8 weeks, followed by 100 mg
daily for life) was generally used prior to the donation.
Furthermore, because of the expense of fluconazole, prior
to the donation those patients deemed to have a poor
prognosis received no antifungal therapy and were
referred for palliative care. The South African protocol for
treating cryptococcal meningitis with donated flucona-
zole was 400 mg daily for 8 weeks followed by 200 mg
daily for life. Amphotericin B for initial therapy up to two
weeks was optional, but was not available in many
smaller hospitals such as ours due largely to intense bed
pressure, difficulty in supervising infusions and monitor-
ing for toxicity. Diflucan®, Pfizer Inc., was used through-
out the study. Amphotericin B (administered at a dose of
0.7 mg/kg/day) was only available at the regional tertiary
referral hospital, but following the donation referrals for
amphotericin B were no longer accepted. Following dis-
charge most patients were referred to their local primary
care clinics for follow up. Antifungal therapy was pro-
vided free to patients throughout the study period. During
the study period there was no public sector access to
antiretroviral therapy.
Patients were identified from computerised laboratory
records if one or more of the following tests of cerebrospi-
nal fluid (CSF) was positive: India Ink stain, cryptococcal
culture and cryptococcal latex agglutination test titre >1:4
(CLAT, Meridian Bioscience, Cincinatti, OH, USA).
Patients were excluded if their HIV status was unknown or
negative, or if they received anti-retroviral therapy. Demo-
graphic characteristics, prior AIDS (World Health Organi-
sation clinical stage 4), baseline clinical and laboratory
data, antifungal treatment, duration of hospitalisation
and outcome were extracted from the medical records.
The level of consciousness at the time of admission was
classified into three stages using a modified version of the
classification used for tuberculous meningitis [12]: stage 1
fully conscious (Glasgow Coma Scale [GCS] 15/15) with-
out neurological deficit, stage 2 focal neurological signs
such as squint or hemiparesis and/or GCS 10–14, and
stage 3 flaccid hemi- or paraplegia and/or GCS below 10/
15. Entries made in the medical records were interpreted
by the first author and when ambiguous by the first two
authors.
Data were analyzed using Stata 8.0 (Stata Corporation,
College Station, Texas, USA). Bivariate associations were
described using chi-square, Fisher's exact and Wilcoxon
rank-sum tests as appropriate. Because we were unable to
ascertain date of death for patients referred to palliative
care facilities, we analysed survival as the time to the com-
bined endpoint of date of death or transfer to the pallia-
tive care facility. Kaplan-Meier survival curves were
generated and survival expressed in days from the date of
diagnosis to the time of death or transfer to a palliative
care facility (failures) or the date of the last visit when the
patient was known to be well (censored). Survival curves
were compared using the log-rank test for the equality of
the survivor function across groups.
The study was approved by the Research Ethics Commit-
tee, University of Cape Town.
Results
A total of 249 patients with cryptococcal meningitis were
identified during the study period: 44 were excluded from
the study (9 missing charts, 19 HIV status not recorded, 5
HIV seronegative, 5 relapsed cryptococcal meningitis, 3
on antiretroviral therapy, 3 CLAT titre ≤1:4) leaving 205
evaluated patients. Demographic, laboratory, clinical andBMC Infectious Diseases 2006, 6:118 http://www.biomedcentral.com/1471-2334/6/118
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antifungal treatment data of the patients before and dur-
ing the donation programme are shown in Table 1. Most
patients were black Africans. Cryptococcal meningitis was
the initial WHO stage 4 condition in 78% of patients.
Sixty-nine percent of patients had prior tuberculosis
(extrapulmonary in 19%), while 41% were receiving anti-
tuberculous treatment at the time of presentation.
CSF pleocytosis (>3 cells/μL) was present in 69% of
patients, with lymphocytic predominance in 82%.
Median CSF leukocyte count was 16 cells/μL. CSF protein
was elevated (>0.4 g/L) in 92% and hypoglycorrhachia
(CSF glucose <2.2 mmol/L) was present in 59%. In total
12 (6%) patients had a normal CSF (no pleiocytosis, pro-
tein ≤0.40 g/L and glucose ≥2.2 mmol/L). CSF pressure
was not recorded due to the absence of manometers. The
median CD4+ T-lymphocyte count was 34 cells/μL (range
3–186), but was only performed in 30 patients.
No significant baseline differences were noted between
patients who received cryptococcal meningitis treatment
prior to or during the fluconazole donation programme
(Table 1). However, when fluconazole became available
through the donation programme there were significant
differences in the antifungal treatment received: more
patients received higher dose fluconazole, no patients
received initial amphotericin B therapy (this was due to a
policy change at the tertiary hospital) and fewer patients
received no antifungal treatment (Table 1). In total 22
patients received no antifungal treatment: 6 died before
treatment (4 in the pre-donation period); 6 patients
received only palliative care (all in the pre-donation
period); 2 did not receive treatment because of health sys-
tem shortages; 5 patients were mis-diagnosed as tubercu-
lous meningitis (2 post-donation); and 3 patients (all
post-donation) did not report for their results of the CSF
examination.
The median duration of the first hospital stay was 5 days.
Fifty-two patients (25%) died during the first hospital
admission after a median of 6 days (range 1–97 days), and
4 patients (2%) were discharged to a palliative care facil-
ity. Of the 149 patients who left the hospital alive and
were not discharged for palliative care, 110 (74%) were
discharged without disability, 27 (18%) had neurological
impairment, and in 12 (8%) the neurological status upon
discharge was not recorded. There were no significant dif-
ferences in length of hospital stay, inpatient mortality or
outcome in the pre- compared with the post-donation
period (Table 2).
Table 1: Clinical and laboratory parameters of patients diagnosed as having AIDS-associated cryptococcal meningitis between January 
1999-March 2001 and from April 2001-December 2002 (before and during the fluconazole donation programme respectively)
Before April 2001 (n = 77) From April 2001 (n = 128) P value
Median age in years (range) 33 (17–75) 35 (21–66) 0.4
Male sex 36 (47%) 63 (49%) 0.7
Prior AIDS-defining illness 20 (26%) 26 (20%) 0.3
Prior tuberculosis 51 (66%) 91 (71%) 0.5
Concurrent TB treatment 33 (43%) 52 (41%) 0.8
CSF India Ink (n = 68) (n = 121) 0.2
Positive 56 (82%) 88 (73%) 0.2
CSF CLAT titer (n = 50) (n = 82) 0.9
≥ 1000 36 (72%) 57 (70%) 0.9
< 1000 14 (28%) 25 (30%)
CSF fungal culture (n = 29) (n = 66) 0.07
Positive 27 (93%) 51 (77%) 0.1
Level of consciousness
Stage 1 45 (58%) 70 (55%) 0.9
Stage 2 30 (39%) 54 (42%)
Stage 3 2 (3%) 4 (3%)
Therapeutic lumbar punctures (n = 7) (n = 23) 0.12
Single 4 14 1.0
Multiple 3 9
Any treatment received
Yes 62 (81%) 121 (95%) <0.01
No 15 (19%) 7 (5%)
Type of initial treatment received (n = 62) (n = 121)
Fluconazole 200 45 (73%) 12 (10%) <0.001
Fluconazole 400 4 (6%) 109 (90%)
Amphotericin B* 13 (21%) 0 (0%)
*This was only available at the local tertiary referral hospital. Following the donation referrals for amphotericin B were no longer accepted.BMC Infectious Diseases 2006, 6:118 http://www.biomedcentral.com/1471-2334/6/118
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In univariate analysis in-hospital mortality was not signif-
icantly different between patients who received initial flu-
conazole 400 mg daily versus fluconazole 200 mg daily
initially (p = 0.4) or between patients who received initial
amphotericin B and fluconazole at any dose (p = 0.9).
Patients who received no antifungal treatment, those with
lower level of consciousness, and CSF CLAT titre > 1,000
had a higher risk of the combined endpoint of in-hospital
death or palliative care facility transfer in the Cox propor-
tional hazard model (Table 3). Patients with Stage 3 level
of consciousness had 100% in-hospital mortality, com-
pared with 43% for those with Stage 2, and 12% for those
with Stage 1. Concomitant anti-tuberculous therapy
including rifampicin, which reduces fluconazole levels by
induction of cytochrome P450 enzymes [13], was not
associated with in-hospital death or palliative care facility
transfer.
Median follow up for the patients discharged from hospi-
tal alive was 36 days. The median survival from time of
cryptococcal meningitis diagnosis was 76 days; 10% of
patients were known to be alive after six months and 3%
after one year. Kaplan-Meier analysis showed no overall
differences in length of survival by initial treatment with
fluconazole 400 mg versus fluconazole 200 mg (p = 0.27
log rank test) (Figure 1); median survival was 76 and 82
days respectively.
Discussion
The fluconazole donation has enabled us to treat all
patients with AIDS-associated cryptococcal meningitis
with antifungal treatment. In addition, it enabled us to
use standard-dose fluconazole. However, despite similar
baseline characteristics, mortality was not significantly
improved by the fluconazole donation. There may have
Table 3: Cox proportional hazard model of time to the combined endpoint of inpatient death or transfer to palliative care facility for 
the first hospital admission.
Variable Hazard ratio (95% confidence interval)
Initial treatment
No treatment 1 (referent)
Amphotericin B 0.23 (0.09–0.61)
Fluconazole 200 0.34 (0.17–0.68)
Fluconazole 400 0.38 (0.21–0.68)
Level of consciousness
Stage 1 1 (referent)
Stage 2 2.51 (1.65–3.8)
Stage 3 5.95 (2.37–14.94)
CSF CLAT titre
≤ 1,000 1 (referent)
> 1,000 1.74 (1.01–3.01)
Concomitant rifampicin 1.21 (0.81–1.8)
Table 2: Inpatient outcomes for the first hospital admission between January 1999 and March 2001 (pre-donation period) and between 
April 2001 and December 2002
Outcome Before April 2001 Pre-
donation n = 77
After April 2001 Donation 
n = 128
P-value for comparison Overall n = 205
Length of hospital stay, 
median days (IQR)
GF Jooste hospital 4 (2.5–9) 5 (3–9) 0.2 5 (3–9)
Tertiary hospital 7 (4–12.5) 4 0.4 7 (4–11.8)
Total hospital stay 6 (4–11) 5 (3–9) 0.4 5 (3–10)
In hospital mortality, n (%) 18 (23.4) 34 (26.6) 0.6 52 (25.4)
Discharge outcome, n (%)
No disability 44 (57.1) 66 (51.6) 0.8 110 (53.7)
Disability 11 (14.3) 16 (12.5) 27 (13.2)
Unspecified disability 3 (3.9) 9 (7) 12 (5.9)
Palliative care 1 (1.3) 3 (2.3) 56 (27.3)BMC Infectious Diseases 2006, 6:118 http://www.biomedcentral.com/1471-2334/6/118
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been other benefits that were not measured in this study.
Firstly, the savings to the pharmaceutical budget were not
calculated. We have previously shown that the net treat-
ment costs of cryptococcal meningitis were $ 2,620, of
which 26% were pharmacy and clinic visit costs [14]. Sec-
ondly, the impact on staff morale was not assessed – deny-
ing patients effective therapy, as was done in the pre-
donation period, is stressful for healthcare professionals.
Thirdly, the fluconazole donation has also allowed appro-
priate treatment for oesophageal candidiasis, which has a
major impact on the quality of life of HIV-infected
patients. The impact in most other sub-Saharan African
countries, where access to antifungal treatment was
extremely limited [7], has presumably been greater than
we observed.
Although our mortality rates are high, they are similar to
those reported from two cohorts from the United States
[2,3]. However the treatment for cryptococcal meningitis
was not specified in the one study [2] and doses of
Amphotericin B varied in the other [3]. Thus it is unclear
what the outcome would be with treatment regarded as
the current standard of care [4]. The mortality we observed
was lower than in the two other African studies where
antifungal treatment was used under standard conditions
(i.e. not in clinical trials). In Zambia [7] the median sur-
vival for those without antifungal treatment was 10 days,
increasing only to 19 days with fluconazole treatment
(400 mg immediate dose followed by 200 mg daily), lead-
ing the authors to conclude "patients receiving flucona-
zole did not show a significant survival advantage". In a
South African study [8] the in-hospital mortality with
antifungal treatment (amphotericin B, sometimes with
flucytosine, or fluconazole – but there was no analysis of
outcomes by treatment group) was 64%. The reasons for
the better survival rates in our study compared with the
other African studies are unclear. Cryptococcal meningitis
was the initial AIDS-defining illness in 78% of our
patients, which is comparable to the 84% found in the
other South African study [8] and the 91% found in Zam-
bia [7]. It is not possible to directly compare level of con-
sciousness on admission, as a marker of late presentation,
as the other studies did not report this in the same manner
we did. Nevertheless, the fact that 13% in the Zambian
Kaplan-Meier survival curves for AIDS-associated cryptococcal meningitis treated with low (200 mg daily) and standard (400  mg daily) dose fluconazole (p = 0.27, log rank test) Figure 1
Kaplan-Meier survival curves for AIDS-associated cryptococcal meningitis treated with low (200 mg daily) and standard (400 
mg daily) dose fluconazole (p = 0.27, log rank test).
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study had confusion [7] and 36% in the other South Afri-
can study had abnormal mental status [8] compared to
44% with grades 2 or 3 level of consciousness in our
study, suggests that this is not the explanation. Therapeu-
tic lumbar punctures, which are thought to improve out-
come [4], were only performed in 15% of patients in our
study, but were not reported in the other two African stud-
ies. We routinely used prophylactic cotrimoxazole
throughout the study period, which was not used in Africa
when the other two studies were done. However,
although cotrimoxazole reduces mortality in South Afri-
can patients with AIDS [15], it is unlikely that it would
have a dramatic impact on early mortality.
None of the patients in this study were receiving antiretro-
viral therapy, which is now becoming available in sub-
Saharan Africa and other developing countries on a wide
scale. Antiretroviral therapy will undoubtedly improve
the prognosis of patients surviving their hospital stay, but
is unlikely to impact on the high in-patient mortality.
Tuberculosis is highly prevalent in HIV-infected patients
in South Africa, as illustrated by the finding that 41% in
our series and 32% in another South African study [8]
were receiving treatment for tuberculosis at the time of
presentation. Cryptococcal meningitis can be misdiag-
nosed as tuberculous meningitis, as occurred in 5 patients
in our series and in 2 of 44 patients in another South Afri-
can study [8]. Rifampicin is a potent inducer of the cyto-
chrome P450 enzyme system, of which fluconazole is a
substrate. Concomitant rifampicin resulted in a 22%
reduction of the fluconazole area under the concentra-
tion-time curve in a Thai study of AIDS-associated crypto-
coccal meningitis [13], but there were no differences in
the rate of CSF cryptococcal culture conversion in the
rifampicin group. However, the authors expressed con-
cern that patients receiving rifampicin whilst on the fluco-
nazole 200 mg daily maintenance dose had fluconazole
concentrations that were below the usual C. neoformans
minimal inhibitory concentration for much of the time
[13]. In our study concomitant rifampicin did not
increase the risk of in-hospital mortality, even in patients
receiving initial therapy with fluconazole 200 mg daily.
There was no difference in outcome between the low-dose
(initial therapy 200 mg daily and maintenance therapy
100 mg daily) and standard-dose (initial therapy 400 mg
daily and maintenance therapy 200 mg daily) fluconazole
groups. We have previously reported 7-month median
survival in patients surviving until hospital discharge
using the low-dose fluconazole strategy in a cohort fol-
lowed up at hospital-based HIV clinics [16]. However we
would not advocate the use of low-dose fluconazole as
this could select for resistance, particularly as we are expe-
riencing increasing MICs to fluconazole, as has been
reported in Cambodia [17].
This study has several limitations. Firstly, it is a retrospec-
tive study and comparisons between different treatment
groups should be made with caution. Secondly, as noted
in the discussion on initial treatment with amphotericin
B, some of the groups were too small to draw meaningful
conclusions. Thirdly, follow-up after hospital discharge
was poor. Our centre was operating largely as an acute
care hospital with very limited outpatient facilities during
the study period. However, most of the analyses were
done on hospital outcomes.
Conclusion
The fluconazole donation has allowed us access to stand-
ard-dose fluconazole treatment for AIDS-associated cryp-
tococcal meningitis. The outcome appeared no better than
when we were selecting patients for low-dose fluconazole
therapy, but other benefits of the fluconazole donation
were not measured. The early mortality in our study was
better than in other African studies. Fluconazole mono-
therapy may be an option in resource-poor settings with
limited access to antifungal therapy.
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